JP2014516702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516702A5 JP2014516702A5 JP2014511881A JP2014511881A JP2014516702A5 JP 2014516702 A5 JP2014516702 A5 JP 2014516702A5 JP 2014511881 A JP2014511881 A JP 2014511881A JP 2014511881 A JP2014511881 A JP 2014511881A JP 2014516702 A5 JP2014516702 A5 JP 2014516702A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically active
- active compound
- exendin
- peptide
- here
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- 108010015174 exendin 3 Proteins 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 101710038873 glc-1 Proteins 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 101700024131 EXE4 Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
Description
本明細書で使用する用語「薬物」または「薬剤」は、少なくとも１つの薬学的に活性な化合物を含む医薬製剤を意味し、
ここで１実施態様において、薬学的に活性な化合物は、最大１５００Ｄａまでの分子量を有し、および／または、ペプチド、タンパク質、多糖類、ワクチン、ＤＮＡ、ＲＮＡ、酵素、抗体もしくはそのフラグメント、ホルモンもしくはオリゴヌクレオチド、または上述の薬学的に活性な化合物の混合物であり、
ここで、さらなる実施態様において、薬学的に活性な化合物は、糖尿病、または糖尿病性網膜症などの糖尿病関連の合併症、深部静脈または肺血栓塞栓症などの血栓塞栓症、急性冠症候群（ＡＣＳ）、狭心症、心筋梗塞、癌、黄斑変性症、炎症、枯草熱、アテローム性動脈硬化症および／または関節リウマチの処置および／または予防に有用であり、
ここで、さらなる実施態様において、薬学的に活性な化合物は、糖尿病または糖尿病性網膜症などの糖尿病に関連する合併症の処置および／または予防のための、少なくとも１つのペプチドを含み、
ここで、さらなる実施態様において、薬学的に活性な化合物は、少なくとも１つのヒトインスリンもしくはヒトインスリン類似体もしくは誘導体、グルカゴン様ペプチド（ＧＬＰ−１）もしくはその類似体もしくは誘導体、またはエキセンジン−３もしくはエキセンジン−４もしくはエキセンジン−３もしくはエキセンジン−４の類似体もしくは誘導体を含む。
ここで１実施態様において、薬学的に活性な化合物は、最大１５００Ｄａまでの分子量を有し、および／または、ペプチド、タンパク質、多糖類、ワクチン、ＤＮＡ、ＲＮＡ、酵素、抗体もしくはそのフラグメント、ホルモンもしくはオリゴヌクレオチド、または上述の薬学的に活性な化合物の混合物であり、
ここで、さらなる実施態様において、薬学的に活性な化合物は、糖尿病、または糖尿病性網膜症などの糖尿病関連の合併症、深部静脈または肺血栓塞栓症などの血栓塞栓症、急性冠症候群（ＡＣＳ）、狭心症、心筋梗塞、癌、黄斑変性症、炎症、枯草熱、アテローム性動脈硬化症および／または関節リウマチの処置および／または予防に有用であり、
ここで、さらなる実施態様において、薬学的に活性な化合物は、糖尿病または糖尿病性網膜症などの糖尿病に関連する合併症の処置および／または予防のための、少なくとも１つのペプチドを含み、
ここで、さらなる実施態様において、薬学的に活性な化合物は、少なくとも１つのヒトインスリンもしくはヒトインスリン類似体もしくは誘導体、グルカゴン様ペプチド（ＧＬＰ−１）もしくはその類似体もしくは誘導体、またはエキセンジン−３もしくはエキセンジン−４もしくはエキセンジン−３もしくはエキセンジン−４の類似体もしくは誘導体を含む。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11167534.4 | 2011-05-25 | ||
| EP11167534 | 2011-05-25 | ||
| PCT/EP2012/059752 WO2012160160A1 (en) | 2011-05-25 | 2012-05-24 | Medicament delivery device with dispense interface sensor and method controlling the device |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516702A JP2014516702A (ja) | 2014-07-17 |
| JP2014516702A5 true JP2014516702A5 (ja) | 2015-07-02 |
| JP6050331B2 JP6050331B2 (ja) | 2016-12-21 |
Family
ID=44856966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511881A Expired - Fee Related JP6050331B2 (ja) | 2011-05-25 | 2012-05-24 | 投薬インターフェース・センサを有する薬剤送達デバイスおよびこのデバイスを制御する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9492616B2 (ja) |
| EP (1) | EP2714147B1 (ja) |
| JP (1) | JP6050331B2 (ja) |
| CN (1) | CN103796696B (ja) |
| DK (1) | DK2714147T3 (ja) |
| WO (1) | WO2012160160A1 (ja) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8157769B2 (en) | 2009-09-15 | 2012-04-17 | Medimop Medical Projects Ltd. | Cartridge insertion assembly for drug delivery system |
| US9643770B2 (en) | 2012-12-03 | 2017-05-09 | Mylan Inc. | System and method for medicament storage, dispensing, and administration |
| US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
| US9179260B2 (en) | 2012-12-03 | 2015-11-03 | Mylan Inc. | Medicament information system and method |
| US9692829B2 (en) | 2012-12-03 | 2017-06-27 | Mylan Inc. | Medication delivery system and method |
| WO2014091765A1 (ja) * | 2012-12-13 | 2014-06-19 | パナソニック株式会社 | 薬剤注入装置 |
| WO2014111332A1 (en) | 2013-01-16 | 2014-07-24 | Bayer Pharma Aktiengesellschaft | Lock for drug injection device |
| CN104936639A (zh) * | 2013-01-29 | 2015-09-23 | 赛诺菲-安万特德国有限公司 | 电子模块和药物输送装置 |
| US10420922B2 (en) * | 2013-02-01 | 2019-09-24 | The Brigham And Women's Hospital, Inc. | Swellable adhesive needles |
| CN105025955B (zh) * | 2013-03-08 | 2017-07-28 | 松下健康医疗控股株式会社 | 药剂注入装置 |
| JP2016538098A (ja) | 2013-10-24 | 2016-12-08 | トラスティーズ オブ ボストン ユニバーシティＴｒｕｓｔｅｅｓ Ｏｆ Ｂｏｓｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 多数の薬剤の誤送出を防止するための注入システム |
| GB2525149A (en) * | 2014-01-30 | 2015-10-21 | Cellnovo Ltd | Therapeutic product delivery device |
| US10441717B2 (en) | 2014-04-15 | 2019-10-15 | Insulet Corporation | Monitoring a physiological parameter associated with tissue of a host to confirm delivery of medication |
| JP6822843B2 (ja) * | 2014-06-03 | 2021-01-27 | アムジエン・インコーポレーテツド | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
| WO2016135236A1 (en) | 2015-02-27 | 2016-09-01 | Novo Nordisk A/S | Accessory device with mounting safety feature |
| CN107683158B (zh) | 2015-06-04 | 2021-05-14 | 麦迪麦珀医疗工程有限公司 | 用于药物释放装置的筒插入 |
| WO2017087888A1 (en) | 2015-11-18 | 2017-05-26 | President And Fellows Of Harvard College | Systems and methods for monitoring, managing, and treating asthma and anaphylaxis |
| RS63450B1 (sr) | 2015-12-30 | 2022-08-31 | Ascendis Pharma As | Auto-injektor sa sistemom za zadržavanje kertridža |
| JP7002465B2 (ja) | 2015-12-30 | 2022-01-20 | アセンディス ファーマ エー／エス | 充電器の安全性を有する自動注射器 |
| CA3006627A1 (en) | 2015-12-30 | 2017-07-06 | Ascendis Pharma A/S | Auto injector with detection of plunger resistance |
| DK3397318T3 (da) | 2015-12-30 | 2022-01-10 | Ascendis Pharma As | Autoinjektor med indstillelig luftskudsmekanisme |
| CA3006622A1 (en) * | 2015-12-30 | 2017-07-06 | Ascendis Pharma A/S | Auto injector with temperature control |
| GB201600229D0 (en) | 2016-01-06 | 2016-02-17 | Vicentra B V | Fluid delivery system |
| AU2017222360B2 (en) * | 2016-02-26 | 2019-08-08 | Eli Lilly And Company | Reusable medication delivery device with remaining medication determination capability |
| WO2017207495A1 (en) * | 2016-05-30 | 2017-12-07 | Novo Nordisk A/S | Mounting feature for accessory device |
| JP6940525B2 (ja) | 2016-05-30 | 2021-09-29 | ノボ・ノルデイスク・エー／エス | ゼロ位置調節特徴を有する薬剤送達デバイス |
| EP3463526A1 (en) | 2016-06-02 | 2019-04-10 | West Pharma. Services Il, Ltd. | Three position needle retraction |
| WO2018026385A1 (en) * | 2016-08-01 | 2018-02-08 | Medimop Medical Projects Ltd. | Partial door closure prevention spring |
| EP3630232A1 (en) | 2017-05-23 | 2020-04-08 | Ascendis Pharma A/S | Auto injector with variable plunger force |
| JP6921997B2 (ja) | 2017-05-30 | 2021-08-18 | ウェスト ファーマ サービシーズ イスラエル リミテッド | ウェアラブル注射器のモジュラ駆動トレイン |
| CN110809484B (zh) * | 2017-06-29 | 2022-07-12 | 阿森迪斯药物股份有限公司 | 具有重构处理支承件的自动注射器 |
| EP3664865B1 (en) * | 2017-08-10 | 2021-06-02 | West Pharma. Services Il, Ltd. | Injector self-test and injector door unlocking mechanism responsive thereto |
| AU2018368338A1 (en) * | 2017-11-16 | 2020-04-09 | Amgen Inc. | Autoinjector with stall and end point detection |
| EP3727514A1 (en) | 2017-12-22 | 2020-10-28 | West Pharma Services IL, Ltd. | Injector usable with different dimension cartridges |
| US11241532B2 (en) | 2018-08-29 | 2022-02-08 | Insulet Corporation | Drug delivery system with sensor having optimized communication and infusion site |
| WO2021046680A1 (zh) * | 2019-09-09 | 2021-03-18 | 郝云玲 | 一种注射装置 |
| CN110548201A (zh) * | 2019-09-09 | 2019-12-10 | 郝云玲 | 一种注射装置 |
| EP4059547A1 (en) * | 2021-03-19 | 2022-09-21 | Ypsomed AG | Contact detection system for an injection device |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1225023A (zh) * | 1996-07-05 | 1999-08-04 | 诺沃挪第克公司 | 剂量设定装置 |
| UA41504C2 (uk) * | 1996-07-05 | 2001-09-17 | Ново Нордіск А/С | Пристрій для доставки відміряних доз лікарського засобу |
| US5993412A (en) * | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US7621893B2 (en) * | 1998-10-29 | 2009-11-24 | Medtronic Minimed, Inc. | Methods and apparatuses for detecting occlusions in an ambulatory infusion pump |
| US7766873B2 (en) * | 1998-10-29 | 2010-08-03 | Medtronic Minimed, Inc. | Method and apparatus for detecting occlusions in an ambulatory infusion pump |
| JP3845857B2 (ja) * | 2001-03-15 | 2006-11-15 | ニプロ株式会社 | 簡易薬液注入器 |
| US7033338B2 (en) * | 2002-02-28 | 2006-04-25 | Smiths Medical Md, Inc. | Cartridge and rod for axially loading medication pump |
| DK1715904T3 (en) * | 2004-02-18 | 2015-11-30 | Ares Trading Sa | Handheld electronically controlled injection device for injection of liquid drugs |
| DK1732627T3 (da) * | 2004-03-31 | 2010-08-16 | Lilly Co Eli | Injektionsapparat, som har en nålekassette til afgivelse af en farmaceutisk væske |
| ES2343810T3 (es) * | 2004-03-31 | 2010-08-10 | Eli Lilly And Company | Aparato de inyeccion que presenta una caja de agujas para administrar un liquido farmaceutico. |
| EP1962947A4 (en) * | 2005-12-20 | 2017-06-28 | Antares Pharma, Inc. | Needle-free injection device |
| US7967785B2 (en) * | 2008-07-14 | 2011-06-28 | Nipro Healthcare Systems, Llc | Insulin reservoir detection via magnetic switching |
| TW201200190A (en) * | 2010-03-26 | 2012-01-01 | Sanofi Aventis Deutschland | Electro-mechanical drug delivery device |
| AU2011335073B2 (en) * | 2010-11-29 | 2015-02-05 | Sanofi-Aventis Deutschland Gmbh | Dispense interface component for a drug delivery device |
-
2012
- 2012-05-24 DK DK12723204.9T patent/DK2714147T3/en active
- 2012-05-24 WO PCT/EP2012/059752 patent/WO2012160160A1/en active Application Filing
- 2012-05-24 CN CN201280037234.2A patent/CN103796696B/zh not_active Expired - Fee Related
- 2012-05-24 JP JP2014511881A patent/JP6050331B2/ja not_active Expired - Fee Related
- 2012-05-24 US US14/119,211 patent/US9492616B2/en active Active
- 2012-05-24 EP EP12723204.9A patent/EP2714147B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516700A5 (ja) | ||
| JP2014519900A5 (ja) | ||
| JP2014516702A5 (ja) | ||
| JP2014516701A5 (ja) | ||
| JP2014527887A5 (ja) | ||
| Poole et al. | Ipragliflozin: first global approval | |
| CY1125006T1 (el) | Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια | |
| Gallwitz | Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes | |
| JP2007517016A5 (ja) | ||
| EA201692282A1 (ru) | Композиция для лечения сахарного диабета, содержащая инсулин и двойной агонист glp-1/глюкагона | |
| JP2014531949A5 (ja) | ||
| JP2018531984A5 (ja) | ||
| JP2019514979A5 (ja) | ||
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| JP2013533268A5 (ja) | ||
| Scheen | GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? | |
| JP2018507914A5 (ja) | ||
| Sanford | Dulaglutide: first global approval | |
| AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
| BR112022013009A2 (pt) | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina | |
| JP2016539921A5 (ja) | ||
| JP2017519739A5 (ja) | ||
| Bain | The clinical development program of lixisenatide: a once-daily glucagon-like peptide-1 receptor agonist | |
| Paccaly et al. | Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects | |
| WO2007124700A3 (en) | Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof |